Skip to content
Download PDF

Histoplasmosis

Chapter 218 | Part 5: Infectious Diseases · Part 5 – Infectious Diseases: Fungal · Chapter 218

Key Clinical Points

  1. Histoplasma capsulatum is a thermal dimorphic fungus endemic to the Ohio and Mississippi river valleys.
  2. Diagnosis relies on Histoplasma antigen detection (>95% sensitivity in progressive disseminated histoplasmosis), culture, and serology.
  3. Treatment for severe disease involves lipid Amphotericin B followed by Itraconazole; mild cases may resolve without therapy.
  4. Progressive disseminated histoplasmosis (PDH) occurs in immunocompromised hosts (e.g., AIDS, transplant) and requires prolonged antifungal therapy.
  5. Fibrosing mediastinitis is a rare but fatal complication characterized by progressive fibrosis around mediastinal structures.
  6. Posaconazole is an effective salvage therapy for refractory cases, though controlled trials are lacking.
  7. Chronic cavitary histoplasmosis mimics tuberculosis and is seen in smokers with structural lung disease.
  8. Serologic tests (ID, CF, EIA) are useful for chronic pulmonary histoplasmosis but may persist for years after infection.
  9. Itraconazole requires therapeutic drug monitoring (target 2–5 μg/mL) due to P450 interactions and variable absorption.
  10. Inactive histoplasmosis does not reactivate in immunocompetent hosts unlike latent tuberculosis.

1. DEFINITION & OVERVIEW

• Pathogen: Endemic mycosis caused by the thermal dimorphic fungus Histoplasma capsulatum. • Dimorphism: Exists as mold in the environment (room temperature) and transforms into yeast form within host tissues. • Clinical Spectrum: Ranges from asymptomatic infection to life-threatening disseminated illness. • Geographic Variants: ◦ North America: H. capsulatum var. capsulatum is the primary agent. ◦ Africa: H. capsulatum var. duboisii causes distinct disease with frequent skin and bone involvement.

2. EPIDEMIOLOGY

• Prevalence: Most prevalent endemic mycosis in North America. • Endemic Regions: Ohio and Mississippi river valleys; sporadic cases in Central/South America, Africa, and Asia. • Environmental Risk: Soil enriched with bird or bat droppings promotes spore growth. • High-Risk Activities: Spelunking, demolition, and cleaning of chicken coops. • Trends: Increasing global incidence due to climate change and increased use of immunosuppressive therapies.

3. ETIOLOGY & PATHOPHYSIOLOGY

• Infection Route: Inhalation of microconidia (2–4 μm) → transformation into yeast forms within macrophages. • Immune Response: ◦ T-cell mediated response involving interferon-γ production. ◦ Activation of macrophages via TNF-α/IL-12 pathways. • Host Defense: In immunocompetent hosts, granuloma formation with calcification provides lifelong immunity. • Dissemination: Occurs in immunocompromised individuals (e.g., AIDS, transplant) via hematogenous spread to the reticuloendothelial system.

3.1 Immune Response and Granuloma Formation

• Timeline: Effective cellular immunity develops ≈ 2 weeks post-exposure. • Mechanism: T cells produce IFN-γ to activate macrophages; IL-12 and TNF-α are critical for immune control. • Outcome: Calcified granulomas in lungs/mediastinum provide long-term protection.

3.2 Dissemination in Immunocompromised Hosts

• PDH Incidence: Occurs in 70% of cases in immunocompromised patients (AIDS, transplant recipients). • Systemic Involvement: Affects multiple organs including lungs, bone marrow, spleen, and adrenal glands. • Predisposing Factors: Structural lung disease (e.g., emphysema) increases risk for chronic cavitary disease.

4. CLINICAL MANIFESTATIONS

• Acute Pulmonary Histoplasmosis: ◦ Incubation: 1–4 weeks. ◦ Symptoms: Flu-like illness (fever, chills, myalgia, dry cough, dyspnea). ◦ Imaging: Hilar adenopathy, focal/diffuse infiltrates. ◦ Extra-pulmonary: 5–10% develop erythema nodosum or arthritis. • Chronic Cavitary Histoplasmosis: ◦ Risk Factors: Smokers with structural lung disease (e.g., bullous emphysema). ◦ Symptoms: Productive cough, weight loss, night sweats. ◦ Imaging: Upper-lobe cavitation and pleural thickening. • Progressive Disseminated Histoplasmosis (PDH): ◦ Risk Factors: CD4+ <200/μL, transplant immunosuppression, anti-TNF therapy. ◦ Symptoms: Fever, hepatosplenomegaly, thrombocytopenia, meningitis. ◦ Prognosis: Rapidly fatal without treatment. • Fibrosing Mediastinitis: ◦ Incidence: 1–2% of cases. ◦ Pathophysiology: Progressive fibrosis around mediastinal lymph nodes. ◦ Complications: SVC syndrome, airway obstruction, hemoptysis. ◦ Mortality: ≈33% due to obstructive complications.

5. DIFFERENTIAL DIAGNOSIS

• Chronic Cavitary Disease: Tuberculosis, aspergillosis, nocardiosis. • PDH: Cryptococcosis, CMV, histoplasmosis in immunocompromised hosts. • Fibrosing Mediastinitis: Sarcoidosis, lymphoma, radiation fibrosis.

6. DIAGNOSTIC APPROACH

  1. Acute Pulmonary (Mild to Moderate):
  2. Test: Histoplasma antigen (BAL fluid, serum, urine), Cytopathology/culture of BAL fluid, Serology (ID, CF, EIA).
  3. Action: If no improvement by time of diagnosis → initiate Itraconazole.
  4. Acute Pulmonary (Severe/ARDS):
  5. Test: Histoplasma antigen (BAL fluid, serum, urine), Cytopathology and fungal culture of BAL fluid, Serology (ID, CF, EIA).
  6. Chronic/Cavitary Pulmonary:
  7. Test: Serology (ID, CF, EIA), Fungal culture of sputum or BAL fluid.
  8. Progressive Disseminated Histoplasmosis (PDH):
  9. Test: Antigen (BAL, serum, urine), Serology (ID, CF, EIA), Fungal culture of blood or bone marrow, Cytopathology on biopsy.
  10. Central Nervous System (CNS):
  11. Test: Antigen in CSF, Serology (ID, CF, EIA), Fungal culture of CSF.

6.1 Diagnostic Tests and Limitations

• Culture: Gold standard; positive in 75% of PDH cases but delayed (up to 1 month). • Antigen Detection: >80% sensitivity for severe pulmonary disease; >95% sensitivity in PDH. • Serology: Useful for chronic disease but limited by delayed antibody response and cross-reactivity.

7. THERAPEUTIC MANAGEMENT

  1. Mild Disease:
  2. Initial Step: Observation or Itraconazole 200 mg bid for 6–12 weeks.
  3. Severe Pulmonary/ARDS:
  4. Induction: Lipid AmB (3–5 mg/kg) for 1–2 weeks.
  5. Maintenance: Itraconazole (200 mg bid) for 6–12 weeks.
  6. Progressive Disseminated Histoplasmosis (PDH):
  7. Induction: Lipid AmB (3–5 mg/kg) for 1–2 weeks.
  8. Maintenance: Itraconazole (200 mg bid); adjust dose to reach blood levels of 2–5 μg/mL for ≥12 months.
  9. Central Nervous System (CNS):
  10. Induction: Liposomal AmB (5 mg/kg) for 4–6 weeks.
  11. Maintenance: Itraconazole (200 mg bid); adjust dose to reach blood levels of 2–5 μg/mL for ≥12 months. Continue until CSF or MRI abnormalities clear.
  12. Monitoring & Adjustments:
  13. Itraconazole: Target trough levels of 2–5 μg/mL; monitor P450 interactions (e.g., warfarin, statins).
  14. General: Monitor renal and hepatic function for all regimens.
  15. Salvage: Posaconazole for refractory cases.

7.1 Drug Regimens and Monitoring

• Itraconazole: Target trough 2–5 μg/mL; monitor P450 interactions. • Lipid AmB: Preferred for severe disease and AIDS patients. • Alternatives: Posaconazole, isavuconazole (avoid fluconazole/voriconazole). • Monitoring: Monitor renal/hepatic function with all regimens.

8. PROGNOSIS & COMPLICATIONS

• Mortality Rates: ◦ Untreated PDH: ≈30%. ◦ Treated cases: 1–2%. ◦ Fibrosing mediastinitis: 33% due to airway obstruction/SVC syndrome. • Relapse Risk: Chronic disease relapse rate of 15–20% without complete treatment (at least 12 months of Itraconazole). • Drug Interactions: Itraconazole interacts with P450 substrates (e.g., warfarin, statins).

9. SPECIAL CONSIDERATIONS

• Itraconazole Administration: Food enhances bioavailability. • Contraindications: Avoid use with rifampin or St. John's wort due to interactions. • Pregnancy: Category C (avoid in first trimester). • Vaccination: No vaccine available for histoplasmosis.

10. CLINICAL TRAPS & PEARLS

• Persistent Serology: May persist for years after infection; does not necessarily indicate active disease. • Fibrosing Mediastinitis: Often misdiagnosed as lymphoma; can be fatal due to SVC syndrome or airway obstruction. • Chronic Treatment Duration: Requires ≥12 months of Itraconazole until radiographic findings stabilize. • Antigen Correlation: Antigen levels correlate with disease activity in PDH.

Reference Tables

TABLE 218-1 Recommendations for the Diagnosis and Treatment of Histoplasmosis

Harrison's 22e, p.1695

TYPE OF
HISTOPLASMOSIS		 DIAGNOSTIC TESTS TREATMENT RECOMMENDATIONS COMMENTS
Acute pulmonary,
mild to moderate with
no improvement by
the time of diagnosis		 Histoplasma antigen (BAL fluid, serum, urine)
Cytopathology and fungal culture of BAL fluid
Histoplasma serology (ID and CF), (EIA):
IgG and IgM		 Itraconazole (200 mg bid) for
6–12 weeks.
Monitor renal and hepatic function.		 Patients with mild cases usually recover without
therapy, but itraconazole should be considered if the
patient’s condition is not already improving by the
time the diagnosis is established.
Histoplasma antigen (BAL fluid, serum, urine)
Cytopathology and fungal culture of BAL fluid
Histoplasma serology (ID and CF), (EIA):
IgG and IgM		 Lipid AmB (3–5 mg/kg per day) ±
glucocorticoids for 1–2 weeks;
then itraconazole (200 mg bid) for
6–12 weeks. Monitor renal and
hepatic function.
Chronic/cavitary
pulmonary		 Histoplasma serology (ID and CF), (EIA):
IgG and IgM
Fungal culture of sputum or BAL fluid		 Itraconazole (200 mg bid) Adjust dose
to achieve blood levels of 2–5 μg/mL
for at least 12 months. Monitor hepatic
function.		 Continue treatment until radiographic findings show
no further improvement. Monitor for relapse after
treatment is stopped.
Histoplasma antigen (BAL fluid, serum, urine)
Histoplasma serology (ID and CF), (EIA):
IgG and IgM
Fungal culture of blood or bone marrow aspirate
Cytopathology on biopsy of affected organ		 Lipid AmB (3–5 mg/kg per day) for
1–2 weeks; then itraconazole (200 mg
bid); adjust dose to achieve blood levels
of 2–5 μg/mL for at least 12 months.
Monitor renal and hepatic function.
Central nervous
system		 Histoplasma antigen CSF
Histoplasma serology (ID and CF), (EIA):
IgG and IgM
Fungal culture of CSF		 Liposomal AmB (5 mg/kg per day) for
4–6 weeks; then itraconazole (200 mg
bid) Adjust dose to achieve blood levels
of 2–5 μg/mL for at least 12 months.
Monitor renal and hepatic function.		 A longer course of lipid AmB is recommended
because of the high risk of relapse. Itraconazole
should be continued until CSF or MRI abnormalities
clear.